Related Experiment Video

Updated: Aug 16, 2026

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Immunoadsorption therapy for a child with Guillain-Barre syndrome subsequent to Mycoplasma infection: a case study

Hirokazu Arakawa1, Yukihiro Yuhara, Makoto Todokoro

  • 1Department of Pediatrics and Developmental Medicine, Gunma University Graduate School, 3-39-15 Showa-machi, Maebashi, Gunma 371, Japan. harakawa@showa.gunma-u.ac.jp

Brain & Development
|August 27, 2005
PubMed

Insights

This study details a case of Guillain-Barre syndrome (GBS) in an 11-year-old boy. Immunoadsorption therapy proved effective for GBS associated with anti-Galactocerebroside (Gal-C) antibodies.

Area of Science:

  • Neurology
  • Immunology
  • Infectious Diseases

Background:

  • Guillain-Barre syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system.
  • The motor axonal form of GBS can lead to severe paralysis and respiratory compromise.
  • Mycoplasma pneumoniae infections are a known trigger for certain GBS subtypes.

Observation:

  • An 11-year-old boy presented with acute, severe paralysis and respiratory insufficiency.
  • Elevated serum IgM antibodies against Mycoplasma pneumoniae and anti-Galactocerebroside (Gal-C) were detected.
  • Magnetic resonance imaging revealed enhancement of the cauda equina.

Findings:

  • The patient exhibited a dramatic response to immunoadsorption therapy using a tryptophan-immobilized column.
  • Significant recovery of respiratory function and muscle strength was observed, particularly in the left extremities.
  • The presence of anti-Gal-C antibodies correlated with the GBS presentation.

Implications:

  • Immunoadsorption therapy is a promising treatment option for anti-Gal-C antibody-associated GBS.
  • Early intervention with immunoadsorption may improve outcomes in severe GBS cases.
  • This case highlights the importance of identifying specific antibody targets in GBS for tailored treatment strategies.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...